期刊
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
卷 35, 期 1, 页码 498-505出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14756366.2019.1710502
关键词
Butyrylcholinesterase; inhibitor; probe; fluorescence
资金
- Slovenian Research Agency [P1-0208, L1-8157, NC-0009]
- French Ministry of Armed Forces (DGA, SSA)
- Agence Nationale de la Recherche (ANR) [ANR-12-BS07-0008-01]
- France Alzheimer Foundation [FA-AAP-2013-65-101349]
- ESRF [MX1788, MX1992]
- Agence Nationale de la Recherche (ANR) [ANR-12-BS07-0008] Funding Source: Agence Nationale de la Recherche (ANR)
Brain butyrylcholinesterase (BChE) is an attractive target for drugs designed for the treatment of Alzheimer's disease (AD) in its advanced stages. It also potentially represents a biomarker for progression of this disease. Based on the crystal structure of previously described highly potent, reversible, and selective BChE inhibitors, we have developed the fluorescent probes that are selective towards human BChE. The most promising probes also maintain their inhibition of BChE in the low nanomolar range with high selectivity over acetylcholinesterase. Kinetic studies of probes reveal a reversible mixed inhibition mechanism, with binding of these fluorescent probes to both the free and acylated enzyme. Probes show environment-sensitive emission, and additionally, one of them also shows significant enhancement of fluorescence intensity upon binding to the active site of BChE. Finally, the crystal structures of probes in complex with human BChE are reported, which offer an excellent base for further development of this library of compounds.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据